months), and class III (16 (19) months) than in class 0-I (22 (24) months) (P < 0-05). Conclusions-Patients with mild, moderate, and severe left ventricular dysfunction benefit from ICD treatment and these patients survive for a considerable time after the first shock. Survival is influenced by the degree of left ventricular dysfunction; aggressive treatment of heart failure is necessary as well as ICD therapy.
Abstract
Objective-To determine whether patients with life threatening ventricular tachyarrhythmias, impaired left ventricular function, and severe heart failure will benefit from implantable cardioverterdefibrillator (ICD) treatment. Design-410 patients were followed up after ICD implant. Left ventricular function was assessed by the New York Heart Association (NYHA) functional class of heart failure: 50 patients (12%) were in NYHA I-II, 151 (37%) in NYHA II, 117 (29%) in NYHA II-III, and 92 (22%) in NYHA III. Epicardial ICD implantation was performed in 209 patients (51%) and 201 patients (49%) received non-thoracotomy ICDs. Results-Perioperatively, 12 patients (3%) died, more often after epicardial ICD implant (11/209 patients, 5%) than after transvenous implant (1/201 patients, < 1%) (P < 0.05). During a mean (SD) follow up of 28 (24) months (range < 1 to 114 months), 90 patients (23%) died: nine (2%) died from sudden arrhythmia; five (1%) also died suddenly but probably not from arrhythmic causes; 55 (14%) died from cardiac causes (congestive heart failure, myocardial reinfarction); 21 (5%) died from non-cardiac causes. The three year, five year, and seven year survival was 92-96% for arrhythmic mortality in NYHA class I, II, and III, compared to a three year survival of 94% and a five year and seven year survival of 84% for patients in NYHA class II-III. 338 patients (82%) received ICD shocks (21 (SD 43) shocks per patient); patients in NYHA class II (83%), class II-III (84%), and class III (90%) received ICD discharges more often than those in class I-II (64%) (P < 0.05). The mean (SD) time interval between ICD implant and the first ICD shock was shorter in NYHA class II (16 (17) months), class II-III (19 (27) months), and class III (16 (19) months) than in class 0-I (22 (24) months) (P < 0-05). Conclusions-Patients with mild, moderate, and severe left ventricular dysfunction benefit from ICD treatment and these patients survive for a considerable time after the first shock. Survival is influenced by the degree of left ventricular dysfunction; aggressive treatment of heart failure is necessary as well as ICD therapy.
(Heart 1997;78:243-249) Keywords: cardioverter-defibrillator; heart failure; sudden death; ICD discharges Sudden cardiac death is one of the major causes of mortality in western countries, with an incidence of 500 000 sudden deaths per year in the United States and 400 000 in Europe. ' 2 It has been shown that the risk of sudden cardiac death increases with the severity of left ventricular dysfunction.35 Although treatment for congestive heart failure has improved markedly during the last 20 years, prognosis is still poor in patients with severe heart failure, with an annual mortality of 50%.6 Several studies have suggested that the implantable cardioverter-defibrillator (ICD) prevents sudden cardiac death in patients with life threatening ventricular tachyarrhythmias and impaired left ventricular function.
However, the extent of the clinical benefit or long term survival is unclear and it is unknown to what extent patients with different degrees of heart failure will benefit from ICD implantation. The present study summarises our experience of ICD treatment in patients with mild, moderate, or severe heart failure during a period of more than 10 years.
Methods

PATIENTS
Four hundred and ten patients (368 male, 42 female), mean (SD) age 57 (11) years (range 10 to 78 years), were consecutively included in the study. Coronary artery disease was present in 279 patients (68%), congestive cardiomyopathy in 76 (19%), left or right ventricular dysplasia in 22 (5%), and the remaining 33 (8%) had another underlying disease (congenital heart disease, valvar heart disease, idiopathic ventricular tachycardia, or ventricular fibrillation). Symptomatic, drug refractory, sustained (duration > 30 seconds) ventricular tachycardia or ventricular fibrillation was present in 403 patients (98%); 15 patients (2%) underwent prophylactic ICD implantation according to the MADIT or CAT study protocols.'01' Antiarrhythmic drug treatment had failed to suppress life threatening ventricular tachyarrhythmias in any of the patients, and they had received a mean of 3-3 (2 7) antiarrhythmic drug trials (range 1-14 drugs per (table 1) . Perioperative deaths (within 30 days after ICD implantation) occurred in 12 patients (3%): one was in NYHA class I-II, four were in class II, five were in class II-III, and the remaining two were in class III. Perioperative deaths occurred more often in patients with epicardial implantation (11/209 patients, 5%) than in those with non-thoracotomy ICDs (1/201 patients, < 1%) (P < 0-05). The cause of perioperative death was congestive heart failure in nine patients, while three patients died from ventricular arrhythmias: one patient from recurrent ventricular fibrillation not treatable by the ICD or additional antiarrhythmic drugs, and two from electromechanical dissociation.
LONG TERM MORTALITY
During a follow up of 28 (24) months (range < 1 to 114 months), 90 patients (23%) died: 14 (4%) died suddenly (within one hour of the beginning of symptoms); nine of these (2%) died from sudden arrhythmic death; five (1%) also died suddenly but probably not from arrhythmic causes. Fifty five patients (14%) died from cardiac causes (congestive heart failure, myocardial reinfarction) and 21 patients (5%) from non-cardiac causes. We have been able to show that the incidence of sudden death was low in all groups (fig 1) . There was 100 --. Survival time (months) Figure 6 Occurrence ofshocks (cumulative) after installation of implantable cardioverter-defibrillator (ICD) in relation to the functional class ofheartfailure. NY, NYHA (New York Heart Association class).
class III. There were no significant differenc in mean survival times after the first shock ai the end of the follow up between patients wi mild (NYHA class I-II), moderate (NYIclass II-III), or severe left ventricular dysfur tion (NYHA class III).
ANTITACHYCARDIA PACING From 1990 we implanted third generati4 ICDs with antitachycardia pacing capabi ties.'4 Because many patients had received fi and second generation devices, antitachycz dia pacing activity was excluded from the pi sent analysis. However, the role antitachycardia pacing in patients with thi generation cardioverter defibrillators has be described in detail by our group elsewhere.'4 ADDITIONAL TREATMENT After cardioverter defibrillator implantation, 153 patients (37%) received digitalis, 230 (56%) were treated with diuretics, and 11 (3%) with ,B blocking agents during follow up. Class I antiarrhythmic drugs (propafenone, mexiletine, flecainide) were given to 28 patients (7%), amiodarone was used in 47 (11%), and 173 (42%) were treated with sotalol; 217 (53%) received angiotensin converting enzyme (ACE) inhibitors (table 2) . There were significant differences in the incidence of digitalis and diuretic treatment between patients with mild, moderate, or severe heart failure (P < 0 05). Patients in NYHA class III received ACE inhibitors more often than patients in NYHA class I-II, II, or II-III; however, these differences were not statistically significant. In addition, no significant differences were observed in the antiarrhythmic drug treatment (class I, amiodarone, sotalol) between the different patient groups.
Discussion
There is little doubt of the efficacy of cardioverter-defibrillator treatment in the termination of life threatening ventricular tachyarrhythmias; however, the benefits of ICD treatment in patients with ventricular tachycardia or ventricular fibrillation and impaired left ventricular function are still unclear. '5 16 There are only two published reports comparing the outcome after ICD 120 treatment in relation to the functional class of heart failure or the degree of left ventricular dysfunction during a relatively short follow Up.17 18 In the present study we report on the outcome after ICD implantation with respect to the functional class of heart failure and left -es ventricular ejection fraction during a long term nd follow up of more than 10 years. In general, ith there are two important aspects of ICD treat-IA ment in patients with impaired left ventricular ic-function: (1) to evaluate the potential benefit of ICD treatment on survival; (2) to see whether the ICD will serve as a "bridge" to heart transplantation in patients with end on stage ventricles who are awaiting a donor ili-heart.'9 rst ar-RISK OF SUDDEN DEATH IN HEART FAILURE re-Previously published data on survival of of patients with ventricular tachyarrhythmias ird treated with antiarrhythmic drugs or antien tachycardia surgery suggest that left ventricular function is an independent predictor of 
